NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Price, News & Analysis

Elevation Oncology logo
$0.63 -0.04 (-5.85%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$0.63 0.00 (-0.02%)
As of 02/7/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Elevation Oncology Stock (NASDAQ:ELEV)

Key Stats

Today's Range
$0.62
$0.68
50-Day Range
$0.56
$0.84
52-Week Range
$0.50
$5.83
Volume
1.22 million shs
Average Volume
3.89 million shs
Market Capitalization
$37.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.20
Consensus Rating
Buy

Company Overview

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Elevation Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

ELEV MarketRank™: 

Elevation Oncology scored higher than 53% of companies evaluated by MarketBeat, and ranked 593rd out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elevation Oncology has only been the subject of 4 research reports in the past 90 days.

  • Read more about Elevation Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Elevation Oncology are expected to decrease in the coming year, from ($0.84) to ($0.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevation Oncology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevation Oncology is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevation Oncology has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Elevation Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    17.19% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Elevation Oncology has recently increased by 38.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elevation Oncology does not currently pay a dividend.

  • Dividend Growth

    Elevation Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.19% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Elevation Oncology has recently increased by 38.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Elevation Oncology has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Elevation Oncology this week, compared to 1 article on an average week.
  • Search Interest

    11 people have searched for ELEV on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • MarketBeat Follows

    19 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 280% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevation Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Elevation Oncology is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elevation Oncology's insider trading history.
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Stock News Headlines

Brokers Offer Predictions for ELEV Q1 Earnings
Elevation Oncology announces CSO departure
Trump’s $500 Billion AI Move—How You Could Profit
With Trump's recent AI announcement, a MASSIVE opportunity has opened up for investors. A $500 billion plan is set to reshape America's tech landscape, involving big players like OpenAI, Oracle, and SoftBank. But here's the best part... For as little as $20, you have the opportunity to get in on this revolutionary project... By investing in an under-the-radar company, set to benefit greatly from this massive AI expansion.
See More Headlines

ELEV Stock Analysis - Frequently Asked Questions

Elevation Oncology's stock was trading at $0.5626 at the beginning of 2025. Since then, ELEV stock has increased by 12.2% and is now trading at $0.6311.
View the best growth stocks for 2025 here
.

Elevation Oncology, Inc. (NASDAQ:ELEV) issued its earnings results on Wednesday, November, 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.02.

Elevation Oncology (ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

Elevation Oncology's top institutional shareholders include Palumbo Wealth Management LLC (0.12%), SG Americas Securities LLC (0.10%) and Millington Financial Advisors LLC (0.08%).
View institutional ownership trends
.

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/06/2024
Today
2/09/2025
Next Earnings (Estimated)
4/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELEV
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.20
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,040.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-45,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
54,330,000
Market Cap
$37.31 million
Optionable
Optionable
Beta
1.31
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ELEV) was last updated on 2/10/2025 by MarketBeat.com Staff
From Our Partners